Journal Article

DZNE-2025-00281

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent.

Karneboge, J. ; Haberstroh, J. ; Geschke, K. ; Perry, J. ; Radenbach, K. ; Jessen, F.DZNE* ; Rostamzadeh, A.

2025
Wiley Hoboken, NJ

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/alz.14204

Abstract: With advances in biomarker-based detection of Alzheimer's disease (AD) and new treatment options with disease-modifying treatments (DMTs), we are heading toward a new conceptualization of diagnostics and therapy in the early stages of AD. Yet consensus guidelines on best clinical practices in predictive AD diagnostics are still developing. Currently, there is a knowledge gap regarding counseling and disclosure practices in early symptomatic disease stages, its implications for dementia risk estimation, and DMTs with associated risks and benefits. The crucial feature is the capacity of patients with (mild) cognitive impairment, eligible for DMTs, to consent. This perspective aims to (1) discuss the current challenges in assessing capacity to consent and (2) highlight the importance of a supported (informed) decision-making process. Measures to facilitate informed decision-making of patients constitute an ethical approach to enhancing the quality of care in this evolving therapeutic landscape. HIGHLIGHTS: This perspective: Explores biomarker-based early symptomatic AD detection and the implications for patient care. Emphasizes supported decision-making in DMTs for MCI and dementia patients. Discusses the need for standardized tools to assess the capacity to consent. Aligns diagnostic and treatment approaches with ethical care standards. Enhances patient autonomy in the evolving AD therapeutic landscape.

Keyword(s): Humans (MeSH) ; Alzheimer Disease: diagnosis (MeSH) ; Alzheimer Disease: therapy (MeSH) ; Alzheimer Disease: drug therapy (MeSH) ; Informed Consent (MeSH) ; Biomarkers (MeSH) ; Cognitive Dysfunction: diagnosis (MeSH) ; Cognitive Dysfunction: therapy (MeSH) ; Decision Making (MeSH) ; Mental Competency (MeSH) ; anti‐amyloid therapy ; biomarkers ; capacity to consent ; communication ; dementia risk estimation ; early diagnosis ; informed consent ; supported decision‐making ; Biomarkers

---

Contributing Institute(s):

1. Clinical Alzheimer’s Disease Research (AG Jessen)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---